Log in

Relevant bibliographies by topics / Feline immunodeficiency virus

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Feline immunodeficiency virus'

Author: Grafiati

Published: 4 June 2021

Last updated: 31 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Feline immunodeficiency virus.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Feline immunodeficiency virus"

1

Hosie, Margaret, Andrew Sparkes, and Cherida Hopper. "Feline immunodeficiency virus." In Practice 11, no. 3 (May 1989): 87–95. http://dx.doi.org/10.1136/inpract.11.3.87.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

ROBINSON, WF, SE SHAW, R. ALEXANDER, and I. ROBERTSON. "Feline immunodeficiency virus." Australian Veterinary Journal 67, no. 8 (August 1990): 278–80. http://dx.doi.org/10.1111/j.1751-0813.1990.tb07796.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Bęczkowski, Paweł M., and Julia A. Beatty. "Feline Immunodeficiency Virus." Advances in Small Animal Care 3, no. 1 (November 2022): 145–59. http://dx.doi.org/10.1016/j.yasa.2022.05.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Legendre, A. M. "Feline leukemia virus & feline immunodeficiency virus." Veterinary Quarterly 18, sup1 (April 1996): 38–39. http://dx.doi.org/10.1080/01652176.1996.9694668.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Michelle Willis, A. "Feline Leukemia Virus and Feline Immunodeficiency Virus." Veterinary Clinics of North America: Small Animal Practice 30, no. 5 (September 2000): 971–86. http://dx.doi.org/10.1016/s0195-5616(00)05001-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

SHIMOJIMA, Masayuki. "Feline immunodeficiency virus tropism." Uirusu 57, no. 1 (2007): 75–82. http://dx.doi.org/10.2222/jsv.57.75.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Pedersen, N. C., J. K. Yamamoto, T. Ishida, and H. Hansen. "Feline immunodeficiency virus infection." Veterinary Immunology and Immunopathology 21, no. 1 (May 1989): 111–29. http://dx.doi.org/10.1016/0165-2427(89)90134-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Miyazawa, Takayuki. "Infections of feline leukemia virus and feline immunodeficiency virus." Frontiers in Bioscience 7, no. 1-3 (2002): d504. http://dx.doi.org/10.2741/miyazawa.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Miyazawa, Takayuki. "Infections of feline leukemia virus and feline immunodeficiency virus." Frontiers in Bioscience 7, no. 4 (2002): d504–518. http://dx.doi.org/10.2741/a791.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Parry, Bruce W., Steven A. Holloway, and Michael J. Studdert. "Diagnosis of Feline Leukemia Virus and Feline Immunodeficiency Virus Infections." Veterinary Clinics of North America: Small Animal Practice 19, no. 4 (July 1989): 719–27. http://dx.doi.org/10.1016/s0195-5616(89)50080-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Feline immunodeficiency virus"

1

Caney, Sarah Madeline Amanda. "Mucosal immunopathogenesis of feline immunodeficiency virus infection." Thesis, University of Bristol, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.341499.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Camerini, Valentina. "Translational control of feline immunodeficiency virus (FIV)." Lyon, École normale supérieure (sciences), 2006. http://www.theses.fr/2006ENSL0387.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Buck, Wayne R. "Neuropathogenic mechanisms of feline immunodeficiency virus infection." Columbus, Ohio : Ohio State University, 2004. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1078414064.

Full text

Abstract:

Thesis (Ph. D.)--Ohio State University, 2004.
Title from first page of PDF file. Document formatted into pages; contains xiv, 144 p.; also includes graphics (some col.). Includes abstract and vita. Co-advisors: Lawrence E. Mathes and Maria H. Neff, Dept. of Veterinary Biosciences. Includes bibliographical references (p. 122-144).

APA, Harvard, Vancouver, ISO, and other styles

4

Leal, Rodolfo Assis Oliveira. "Recombinant feline interferon omega therapy in cats naturally infected with Feline Immunodeficiency Virus : clinical, viral and immunological relevance." Doctoral thesis, Universidade de Lisboa. Faculdade de Medicina Veterinária, 2014. http://hdl.handle.net/10400.5/7458.

Full text

Abstract:

Tese de Doutoramento em Ciências Veterinárias Especialidade de Clínica
Type-I Interferons are well-known cytokines which among their main functions are key components of the host immune response against viral infections. Due to its immune modulation properties, they are commonly used in the therapeutic approach of various diseases such as retroviral infections. Recombinant feline interferon omega (rFeIFN-ω) is the first interferon licensed for use in veterinary medicine. Although it is commonly administered in retroviral infections, namely in Feline Immunodeficiency Virus (FIV) and Feline Leukemia Virus (FeLV) infected cats, few studies reported its clinical benefits and mechanisms of action. This thesis aims to clarify the main properties of the licensed rFeIFN-ω protocol (3 cycles of 5 daily subcutaneous administrations of 1MU/kg beginning on days 0, 14 and 60) in naturally retroviral infected cats living in an animal shelter, evaluating its effect not only on clinical improvement but also on concurrent viral excretion, viremia/proviral load and various immune biomarkers such as acute phase proteins and cytokine profile. Recognizing the non specific and subtle clinical presentation of the majority of FIV-infected cats, this work also presents and evaluates an alternative oral rFeIFN-ω protocol (0.1MU/cat during 90 days) to be used in client-owned FIV-infected cats. Results showed that the licensed rFeIFN-ω protocol induces a significant clinical improvement, with a concurrent reduction of opportunistic viral infections and an increase on acute phase proteins (APP) profile. The alternative protocol also revealed an important clinical improvement but without significant changes on opportunistic viral infections (which were of low level in the tested group) or on APP profile. In both protocols, no changes were remarked on viremia neither on T-helper 1/T-helper 2 cytokine profiles meaning that this compound may lack an anti-viral activity for retroviruses in vivo and do not act on the acquired immune response of FIV-positive cats. However, there was a significant reduction of the interleukin-6 plasma levels (pro-inflammatory cytokine) in cats treated with the licensed protocol and a decrease on its mRNA expression in cats treated orally. This shows that rFeIFN-ω can have anti-inflammatory properties, which are more evident in the higher doses of the licensed protocol. More than contributing for a better knowledge of rFeIFN-ω, this thesis explores its immune modulation properties and validates a new oral protocol which can be included on future FIV-guidelines.
Resumo - A terapêutica com interferão ómega felino em gatos naturalmente infectados com o vírus da imunodeficiência felina: relevância clinica, virológica e imunitária - Os interferões do tipo I são citoquinas chave do sistema imunitário. Devido às suas propriedades imunomoduladoras, são um recurso terapêutico frequente em diferentes doenças como as infecções retrovirais. O interferão ómega felino (rFeIFN-ω) é o primeiro interferão licenciado para medicina veterinária. Apesar do seu uso no tratamento de infeções retrovirais como o vírus da imunodeficiência felina (FIV) e o vírus da leucemia felina (FeLV), são poucos os estudos que fundamentam o seu benefício clinico. Esta tese visa clarificar as propriedades terapêuticas e imunomoduladoras do protocolo licenciado de rFeIFN-ω (3 ciclos de 5 administrações subcutâneas de 1MU/kg uma vez ao dia a iniciar aos dias 0, 14 e 60) em gatos naturalmente infectados por retrovírus e residentes em gatil. Em detalhe, este trabalho avalia o efeito deste fármaco na melhoria clinica, na excreção de vírus concomitantes, na virémia/provirus e na variação de diferentes marcadores imunitários como proteínas de fase aguda e perfil de citoquinas. Esta tese contempla ainda o desenvolvimento de um protocolo terapêutico alternativo baseado na administração oral de rFeIFN-ω (0.1MU/gato durante 90 dias consecutivos) para uso em gatos FIV-positivos domésticos, os quais apresentam geralmente um quadro clinico subtil e pouco específico. Os resultados revelaram que o protocolo licenciado induz uma melhoria clinica significativa com redução concomitante das infecções oportunistas e um aumento do perfil de proteínas de fase aguda (APP). O protocolo alternativo revelou-se eficaz na melhoria clinica dos animais tratados, apesar de não induzir alterações significativas do perfil de APPs nem das infecções concomitantes (residuais no grupo de estudo). Ambos os protocolos não induziram alterações na virémia nem no perfil de citoquinas participantes nas respostas T-helper 1 ou T-helper 2 o que sugere que este composto não apresenta propriedades anti-virais nem actua na imunidade adquirida de gatos FIV positivos. Verificou-se contudo um decréscimo dos niveis plasmáticos de Interleucina-6 (citoquina pro-inflamatória) em gatos tratados com o protocolo subcutâneo e uma redução da sua expressão (mRNA) em gatos tratados por vira oral. Tal demonstra que o rFeIFN-ω apresenta propriedades anti-inflamatórias, as quais são mais evidentes aquando do tratamento com o protocolo licenciado. Mais que uma contribuição para um melhor conhecimento do rFeIFN-ω, esta tese explora as suas propriedades imunomoduladoras e valida um novo protocolo oral, o qual poderá ser incluído em futuras guidelines para o tratamento de gatos FIV-positivos.
Trabalho financiado também pelo Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA) da Faculdade de Medicina Veterinária, Universidade de Lisboa e Virbac (Centro de Custos phD_Virbac).

APA, Harvard, Vancouver, ISO, and other styles

5

Haining, Hayley. "Studies of the pathogenesis of feline immunodeficiency virus." Thesis, University of Glasgow, 2004. http://theses.gla.ac.uk/5512/.

Full text

Abstract:

The project had three aims: namely: - (i) to investigate the in vitro cell tropism of a range of field isolates from cats at different stages of disease and compare their phenotype with the well-characterised prototype viruses FIV-PET and FIV-GL8. (ii) to study the pathogenicity of these viruses in vivo in order to examine any correlation between virulence in vivo and tropism in vitro. (iii) to look at the role of the env gene in the pathogenicity of FIV. In vitro studies of cell tropism revealed that isolates from cats in the terminal stage of disease had a greater ability to utilise CXCR4 than isolates from cats displaying no clinical signs. In vivo, these symptomatic isolates, with greater CXCR4-tropism in vitro, displayed less virulence when compared with isolates from asymptomatic cats. Chimaeras were made by inserting the env genes of an isolate from the asymptomatic or terminal disease stages into a FIV-G8Mya backbone, allowing comparison of the cell tropism and receptor usage of these genes and the study of their phenotype with regard to virulence in vivo. The env genes from FIV-PET and the symptomatic isolate (F0827Hs) had a greater affinity to utilise CXCR4 for cell entry in vitro and this correlated with reduced virulence in vivo when compared to the asymptomatic isolate env and FIV-G8Mya. These studies highlight a trend where tropism in vitro can be correlated with virulence in vivo. Furthermore, the study indicated that viruses from asymptomatic cats (with a lesser ability to utilise CXCR4) have increased virulence. As these are the agents most likely to be transmitted in the field by the apparently healthy cat, vaccine development should focus on this population of viruses.

APA, Harvard, Vancouver, ISO, and other styles

6

Gemeniano, Maria Lourdes Charmaine. "Characterization of Orf-A of feline immunodeficiency virus /." For electronic version search Digital dissertations database. Restricted to UC campuses. Access is free to UC campus dissertations, 2002. http://uclibs.org/PID/11984.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bęczkowski, Paweł. "Virus evolution in the progression of natural feline immunodeficiency virus infection." Thesis, University of Glasgow, 2013. http://theses.gla.ac.uk/4186/.

Full text

Abstract:

Feline immunodeficiency virus (FIV) is an important pathogen of domestic cats which in some cases can lead to feline AIDS. It shares many similarities with its human counterpart and is studied to understand correlates of immune-protection and mechanisms of disease progression in cats, both to improve the welfare of infected cats and as an animal model for the pathogenesis of HIV infection in humans. FIV is believed to evolve during the course of infection as a result of the error prone nature of reverse transcriptase and recombination between viral variants, but relatively little is known about this process in naturally occurring infection. Ultimately, it remains unknown why some infected cats remain healthy while others progress to AIDS rapidly. The studies reported in this thesis addressed this lack of knowledge by examining sequential blood samples obtained during the course of natural FIV infection in a population of 44 privately owned domestic cats. Employing Bayesian coalescent framework, it was demonstrated that the FIV env gene is relatively stable genetically. Although not necessary a prerequisite, this is likely to explain why many naturally infected cats can remain healthy and do not progress to AIDS. By determining the cell tropism of isolated viral variants, it was shown that sick cats were more likely to harbour viruses of the “late” phenotype than healthy animals, similar to the co-receptor switch observed during the progression of HIV infection. Intra-host diversity analyses highlighted a likely role for the leader region of the env gene in viral pathogenesis. Furthermore, recombination was demonstrated to be abundant in natural infection, indicating a requirement for the current phylogenetic classification of FIV to be revised. By assessing the strength and breadth of neutralising antibodies (NAbs), it was shown that NAbs did not appear to influence the course of natural FIV infection, arguing against a role in controlling infection and disease progression. Following an examination of samples collected from a group of privately owned Australian vaccinates, it was shown that the Fel-O-Vax FIV vaccine did not induce cross-reactive neutralising antibodies. Furthermore, in the country where commercial FIV vaccine is licenced, we identified and characterised the virus strain which was likely able to establish infection in vaccinated cat and raised concerns of vaccine’s efficacy. Overall this study broadens our understanding of natural FIV infection, and highlights that much can be learned, not from the similarities but rather by studying the differences between the feline and human lentiviruses. Such comparative studies are likely to contribute to design of highly desirable, safe and fully efficacious lentiviral vaccines.

APA, Harvard, Vancouver, ISO, and other styles

8

Chan, Chi Ngai. "Cell signalling and feline immunodeficiency virus growth and latency." Thesis, University of Glasgow, 2013. http://theses.gla.ac.uk/3889/.

Full text

Abstract:

The replication of CD4+ T cell-tropic retroviruses such as the human immunodeficiency virus-1 (HIV-1) and the feline immunodeficiency virus (FIV) is intricately linked to host cell signalling and activation status. This intimate relationship between the viruses and their respective hosts plays crucial roles in the pathogenesis of each virus. Focusing on FIV, this thesis examined several questions relating to virus replication and cell signalling. Firstly, the possible cell stimulatory effect when FIV Env binds to its primary receptor CD134 was investigated and results suggested that FIV does not trigger CD134 signalling. Next the activation status of susceptible CD4+ T cells was manipulated to study FIV latency and it was shown that by removing exogenous supplement of the cytokine interleukin-2 (IL-2) from MYA-1 feline CD4+ T cells 24 hours before infection, productive FIV replication is down-regulated such that only a very low level of ongoing virus replication can be detected among the IL-2-depleted cells with a sensitive qPCR assay. The phorbol esters PMA and Prostratin can stimulate high level of productive infection from these IL-2-depleted MYA-1 cells and this is mediated by a protein kinase C (PKC) dependent mechanism. Furthermore, productive replication of FIV in the presence of IL-2 is blocked by stimulation of PKC with phorbol esters, which is analogous to findings of similar experiments with HIV-1. However, inhibition of viral replication is not at the level of viral entry, contrary to the findings of HIV-1 studies. The mechanism behind the Prostratin-mediated inhibition of FIV remains elusive. It was also discovered that ‘early’ and ‘late’ strains of FIV responded differently to cell signalling manipulation and an attempt was made to map the viral genome region(s) responsible. Preliminary data showed that both env and the 5’UTR may mediate the inter-strain differences in replication dynamics. Overall this thesis shows the complete dependency of FIV on host cell signalling, in particular optimum PKC activation to achieve productive viral replication. This may reflect the tropism of the virus. The similarities between HIV-1 and FIV replication and latency support the notion of using FIV and the cat as a model for HIV-1 latency in the development of novel therapeutic measures to eradicate hidden HIV-1 from the host. However, more research is required to fully characterise the differences between HIV-1 and FIV biology.

APA, Harvard, Vancouver, ISO, and other styles

9

Grant, Susan Elizabeth. "Studies on haemopoiesis in early feline immunodeficiency virus infection." Thesis, University of Glasgow, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.296042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Samman, Ayman. "The role of virus neutralisation in immunity to feline immunodeficiency virus infection." Thesis, University of Glasgow, 2010. http://theses.gla.ac.uk/1554/.

Full text

Abstract:

Feline immunodeficiency virus (FIV) is an important veterinary pathogen with comparative significance because of its similarities to its human counterpart HIV. Since FIV is the only non-primate lentivirus which induces AIDS-like symptoms in its natural host, it serves as a valuable animal model for both prophylactic and therapeutic studies of HIV. It is accepted that the induction of neutralising antibodies (NAbs) is a key element in the control of lentiviral infection, since T-cell based vaccines alone failed to prevent infection in most experimental animal model systems. In this project a robust and reproducible in vitro neutralisation assay was developed and optimised, permitting the assessment of the NAb response in naturally infected cats and with the potential to evaluate candidate vaccines. It was demonstrated that, in general, primary FIV strains in the UK belong to subtype A, and therefore the development of a regional, subtype A-specific, FIV vaccine could be considered for use in the UK. The identification of a neutralisation resistant isolate of FIV led to the finding that a linear neutralisation determinant was located within the V5 region of Env and mutations in this region may lead to immune evasion in vivo. In addition, a second neutralisation determinant was identified in the C3/V4 region of Env. Finally, it was observed that a small proportion of naturally infected cats generated NAbs against FIV. Of these, only a very small proportion of the cats had antibodies with the potential to cross neutralise strains within the same subtype as the homologous isolate. Nonetheless, a plasma sample from a single cat was identified that neutralised all strains tested, including strains from different subtypes and geographical regions. It is likely that studies of the homologous isolate that induced the broad NAb response may be capable of inducing a similar broad response in vaccinated cats. Such a finding would have important implications for the design of potential novel lentiviral immunogens.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Feline immunodeficiency virus"

1

American Association of Feline Practitioners and Academy of Feline Medicine Advisory Panel on Feline Retrovirus Testing and Management. 2001 report of the American Association of Feline Practitioners and Academy of Feline Medicine Advisory Panel on feline retrovirus testing and management. Nashville, TN: American Association of Feline Practitioners/Academy of Feline Medicine, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

J, Willett B., and Jarrett O, eds. Feline immunology and immunodeficiency. Oxford: Oxford University Press, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ian, Phillips M., ed. Gene therapy methods. San Diego, Calif: Academic Press, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Phillips, M. Ian. Gene Therapy Methods. Elsevier Science & Technology Books, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Feline immunodeficiency virus"

1

Viita-aho, Teija Kaarina. "Feline Immunodeficiency Virus." In Nursing the Feline Patient, 182–84. Ames, Iowa, USA: John Wiley & Sons, Inc, 2016. http://dx.doi.org/10.1002/9781119264910.ch24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Pedersen, Niels C. "The Feline Immunodeficiency Virus." In The Retroviridae, 181–228. Boston, MA: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4899-1627-3_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Gershwin, Laurel J. "Case 9: Feline Immunodeficiency Virus." In Case Studies in Veterinary Immunology, 35–38. New York, NY : Garland Science, [2017]: Garland Science, 2017. http://dx.doi.org/10.4324/9781315165462-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Hosie, M. J., and O. Jarrett. "Feline Immunodeficiency Virus as a Vaccine Model." In Vaccines, 85–95. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4613-0357-2_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Gardner, M. B., and S. Dandekar. "Neurobiology of Simian and Feline Immunodeficiency Virus Infections." In Current Topics in Microbiology and Immunology, 135–50. Berlin, Heidelberg: Springer Berlin Heidelberg, 1995. http://dx.doi.org/10.1007/978-3-642-79657-9_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bendinelli, M., M. Pistello, D. Matteucci, S. Lombardi, F. Baldinotti, P. Bandecchi, R. Ghilarducci, et al. "Small Animal Model of AIDS and the Feline Immunodeficiency Virus." In Advances in Experimental Medicine and Biology, 189–202. Boston, MA: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-2980-4_27.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Farmerie, W. G., M. M. Goodenow, and B. M. Dunn. "Cloning, Expression and Kinetic Characterization of the Feline Immunodeficiency Virus Proteinase." In Advances in Experimental Medicine and Biology, 511–13. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-6012-4_67.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Rackwitz, H. R., M. Schnölzer, J. H. Elder, and S. B. H. Kent. "Proteolytic activity of feline immunodeficiency virus protease prepared by total chemical synthesis." In Peptides 1994, 347–48. Dordrecht: Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-011-1468-4_154.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Henriksen, S. J., O. Prospero-Garcia, T. R. Phillips, H. S. Fox, F. E. Bloom, and J. H. Elder. "Feline Immunodeficiency Virus as a Model for Study of Lentivirus Infection of the Central Nervous System." In Current Topics in Microbiology and Immunology, 167–86. Berlin, Heidelberg: Springer Berlin Heidelberg, 1995. http://dx.doi.org/10.1007/978-3-642-79657-9_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Sherding, Robert G. "Feline Immunodeficiency Virus." In Saunders Manual of Small Animal Practice, 126–31. Elsevier, 2006. http://dx.doi.org/10.1016/b0-72-160422-6/50011-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Feline immunodeficiency virus"

1

Statsi, M., and Y. Melnikova. "THE DEPENDENCE ON GENDER OF THE INCIDENCE OF FELINE VIRAL IMMUNODEFICIENCY AND FELINE VIRAL LEUKEMIA." In SAKHAROV READINGS 2022: ENVIRONMENTAL PROBLEMS OF THE XXI CENTURY. International Sakharov Environmental Institute of Belarusian State University, 2022. http://dx.doi.org/10.46646/sakh-2022-2-91-93.

Full text

Abstract:

The prevalence of feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) in the populations of domestic and homeless cats has been analyzed. The effectiveness of diagnostic methods used for the detection of feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) has been studied. It was found that the level of prevalence of viral diseases of cats, such as the immunodeficiency virus and the leukemia virus, depends on the lifestyle, gender, and health status of cats; the diagnosis of the immunodeficiency virus and the leukemia virus depends on the economic situation of the country and the commercial availability of test systems; Widespread vaccination has proven its effectiveness and the possibility of limiting the risks of infection. PCR is the gold standard in the diagnosis of viral diseases, but it is an expensive method.

APA, Harvard, Vancouver, ISO, and other styles

2

Sidoni, Marli, Aline Bernardo, Edmilson Silva, Maria Azevedo, Patricia Jurgilas, Ana Araújo, Hilton Nascimento, Jose Silva Junior, Carlos Mazur, and Maria Danelli. "Rapid Immunochromatographic test for serological diagnosis of Feline Immunodeficiency Virus in cats." In III Seminário Anual Científico e Tecnológico de Bio-Manguinhos. Instituto de Tecnologia em Imunobiológicos, 2015. http://dx.doi.org/10.35259/isi.sact.2015_28494.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Cohen, Brian, Anand Gadre, and Alain E. Kaloyeros. "Design, fabrication, and characterization of polymeric bioMEMS for the detection of feline immunodeficiency virus (FIV)." In Biomedical Optics (BiOS) 2007, edited by Tuan Vo-Dinh, Warren S. Grundfest, David A. Benaron, Gerald E. Cohn, and Ramesh Raghavachari. SPIE, 2007. http://dx.doi.org/10.1117/12.700879.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!